共 50 条
Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis
被引:3
|作者:
Ozola, Lota
[1
,2
]
Aleksejeva, Elina
[1
,2
]
Stoldere, Diana
[1
,2
,5
]
Davidsone, Zane
[1
,2
]
Santere, Ruta
[2
]
Grantina, Ineta
[1
,2
]
Cirule, Ieva
[1
,2
]
Krams, Alvils
[3
,4
]
机构:
[1] Riga Stradins Univ, Dept Paediat, Riga, Latvia
[2] Childrens Clin Univ Hosp, Clin Pediat Dis, Riga, Latvia
[3] Riga East Clin Univ Hosp, Ctr TB & Lung Dis, Riga, Latvia
[4] Univ Latvia, Dept Internal Med, Riga, Latvia
[5] Childrens Clin Univ Hosp, Vienibas gatve 45, LV-1004 Riga, Latvia
关键词:
mepolizumab in pediatrics;
pediatric EGPA;
small vessel vasculitis;
CHURG-STRAUSS-SYNDROME;
AMERICAN-COLLEGE;
ALLERGIC GRANULOMATOSIS;
CHILDHOOD;
CLASSIFICATION;
CRITERIA;
D O I:
10.1002/ppul.26249
中图分类号:
R72 [儿科学];
学科分类号:
100202 ;
摘要:
Eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) is classified as an antineutrophil cytoplasmic antibody (ANCA)-associated small vessel vasculitis. It is a multisystem disorder and can affect every organ system. EGPA is a rare disease, with an estimated prevalence of 1/70,000-100,000 in Europe. As its onset usually occurs in adulthood, data from pediatric patients are limited. We present here a very rare practical EGPA clinical case involving a pediatric patient. Presently, data on mepolizumab usage in pediatric patients are limited, with only a few case reports published.
引用
收藏
页码:973 / 979
页数:7
相关论文